Liraglutide  ||| S:0 E:12 ||| NNP
for  ||| S:12 E:16 ||| IN
the  ||| S:16 E:20 ||| DT
treatment  ||| S:20 E:30 ||| NN
of  ||| S:30 E:33 ||| IN
type  ||| S:33 E:38 ||| NN
2  ||| S:38 E:40 ||| CD
diabetes  ||| S:40 E:49 ||| NN
This  ||| S:49 E:54 ||| DT
paper  ||| S:54 E:60 ||| NN
presents  ||| S:60 E:69 ||| VBZ
a  ||| S:69 E:71 ||| DT
summary  ||| S:71 E:79 ||| NN
of  ||| S:79 E:82 ||| IN
the  ||| S:82 E:86 ||| DT
evidence  ||| S:86 E:95 ||| NN
review  ||| S:95 E:102 ||| NN
group  ||| S:102 E:108 ||| NN
( ||| S:108 E:109 ||| -LRB-
ERG ||| S:109 E:112 ||| NNP
)  ||| S:112 E:114 ||| -RRB-
report  ||| S:114 E:121 ||| NN
into  ||| S:121 E:126 ||| IN
the  ||| S:126 E:130 ||| DT
clinical  ||| S:130 E:139 ||| JJ
effectiveness  ||| S:139 E:153 ||| NN
and  ||| S:153 E:157 ||| CC
cost-effectiveness  ||| S:157 E:176 ||| JJ
of  ||| S:176 E:179 ||| IN
liraglutide  ||| S:179 E:191 ||| NN
in  ||| S:191 E:194 ||| IN
the  ||| S:194 E:198 ||| DT
treatment  ||| S:198 E:208 ||| NN
of  ||| S:208 E:211 ||| IN
type  ||| S:211 E:216 ||| NN
2  ||| S:216 E:218 ||| CD
diabetes  ||| S:218 E:227 ||| NN
mellitus ||| S:227 E:235 ||| NN
,  ||| S:235 E:237 ||| ,
based  ||| S:237 E:243 ||| VBN
upon  ||| S:243 E:248 ||| IN
the  ||| S:248 E:252 ||| DT
manufacturer ||| S:252 E:264 ||| NN
's  ||| S:264 E:267 ||| POS
submission  ||| S:267 E:278 ||| NN
to  ||| S:278 E:281 ||| TO
the  ||| S:281 E:285 ||| DT
National  ||| S:285 E:294 ||| NNP
Institute  ||| S:294 E:304 ||| NNP
for  ||| S:304 E:308 ||| IN
Health  ||| S:308 E:315 ||| NNP
and  ||| S:315 E:319 ||| CC
Clinical  ||| S:319 E:328 ||| NNP
Excellence  ||| S:328 E:339 ||| NNP
( ||| S:339 E:340 ||| -LRB-
NICE ||| S:340 E:344 ||| NNP
)  ||| S:344 E:346 ||| -RRB-
as  ||| S:346 E:349 ||| IN
part  ||| S:349 E:354 ||| NN
of  ||| S:354 E:357 ||| IN
the  ||| S:357 E:361 ||| DT
single  ||| S:361 E:368 ||| JJ
technology  ||| S:368 E:379 ||| NN
appraisal  ||| S:379 E:389 ||| NN
process ||| S:389 E:396 ||| NN
.  ||| S:396 E:398 ||| .
The  ||| S:398 E:402 ||| DT
manufacturer  ||| S:402 E:415 ||| NN
proposed  ||| S:415 E:424 ||| VBD
the  ||| S:424 E:428 ||| DT
use  ||| S:428 E:432 ||| NN
of  ||| S:432 E:435 ||| IN
liraglutide  ||| S:435 E:447 ||| NN
as  ||| S:447 E:450 ||| IN
a  ||| S:450 E:452 ||| DT
second  ||| S:452 E:459 ||| JJ
or  ||| S:459 E:462 ||| CC
third  ||| S:462 E:468 ||| JJ
drug  ||| S:468 E:473 ||| NN
in  ||| S:473 E:476 ||| IN
patients  ||| S:476 E:485 ||| NNS
with  ||| S:485 E:490 ||| IN
type  ||| S:490 E:495 ||| NN
2  ||| S:495 E:497 ||| CD
diabetes  ||| S:497 E:506 ||| NN
whose  ||| S:506 E:512 ||| WP$
glycaemic  ||| S:512 E:522 ||| JJ
control  ||| S:522 E:530 ||| NN
was  ||| S:530 E:534 ||| VBD
unsatisfactory  ||| S:534 E:549 ||| VBN
with  ||| S:549 E:554 ||| IN
metformin ||| S:554 E:563 ||| NN
,  ||| S:563 E:565 ||| ,
with  ||| S:565 E:570 ||| IN
or  ||| S:570 E:573 ||| CC
without  ||| S:573 E:581 ||| IN
a  ||| S:581 E:583 ||| DT
second  ||| S:583 E:590 ||| JJ
oral  ||| S:590 E:595 ||| JJ
glucose-lowering  ||| S:595 E:612 ||| JJ
drug ||| S:612 E:616 ||| NN
.  ||| S:616 E:618 ||| .
The  ||| S:618 E:622 ||| DT
submission  ||| S:622 E:633 ||| NN
included  ||| S:633 E:642 ||| VBD
six  ||| S:642 E:646 ||| CD
manufacturer-sponsored  ||| S:646 E:669 ||| JJ
trials  ||| S:669 E:676 ||| NNS
that  ||| S:676 E:681 ||| IN
compared  ||| S:681 E:690 ||| VBN
the  ||| S:690 E:694 ||| DT
efficacy  ||| S:694 E:703 ||| NN
of  ||| S:703 E:706 ||| IN
liraglutide  ||| S:706 E:718 ||| NN
against  ||| S:718 E:726 ||| IN
other  ||| S:726 E:732 ||| JJ
glucose-lowering  ||| S:732 E:749 ||| JJ
agents ||| S:749 E:755 ||| NNS
.  ||| S:755 E:757 ||| .
Not  ||| S:757 E:761 ||| RB
all  ||| S:761 E:765 ||| RB
of  ||| S:765 E:768 ||| IN
the  ||| S:768 E:772 ||| DT
trials  ||| S:772 E:779 ||| NNS
were  ||| S:779 E:784 ||| VBD
relevant  ||| S:784 E:793 ||| JJ
to  ||| S:793 E:796 ||| TO
the  ||| S:796 E:800 ||| DT
decision  ||| S:800 E:809 ||| NN
problem ||| S:809 E:816 ||| NN
.  ||| S:816 E:818 ||| .
The  ||| S:818 E:822 ||| DT
most  ||| S:822 E:827 ||| RBS
relevant  ||| S:827 E:836 ||| JJ
were  ||| S:836 E:841 ||| VBD
Liraglutide  ||| S:841 E:853 ||| NNP
Effects  ||| S:853 E:861 ||| NNPS
and  ||| S:861 E:865 ||| CC
Actions  ||| S:865 E:873 ||| NNP
in  ||| S:873 E:876 ||| IN
Diabetes  ||| S:876 E:885 ||| NNP
5  ||| S:885 E:887 ||| CD
( ||| S:887 E:888 ||| -LRB-
LEAD-5 ||| S:888 E:894 ||| NNP
)  ||| S:894 E:896 ||| -RRB-
( ||| S:896 E:897 ||| -LRB-
liraglutide  ||| S:897 E:909 ||| VB
used  ||| S:909 E:914 ||| VBN
as  ||| S:914 E:917 ||| IN
part  ||| S:917 E:922 ||| NN
of  ||| S:922 E:925 ||| IN
triple  ||| S:925 E:932 ||| JJ
therapy  ||| S:932 E:940 ||| NN
and  ||| S:940 E:944 ||| CC
compared  ||| S:944 E:953 ||| VBN
against  ||| S:953 E:961 ||| IN
insulin  ||| S:961 E:969 ||| NN
glargine ||| S:969 E:977 ||| NN
)  ||| S:977 E:979 ||| -RRB-
and  ||| S:979 E:983 ||| CC
LEAD-6  ||| S:983 E:990 ||| NNP
[ ||| S:990 E:991 ||| -LRB-
liraglutide  ||| S:991 E:1003 ||| NN
in  ||| S:1003 E:1006 ||| IN
triple  ||| S:1006 E:1013 ||| JJ
therapy  ||| S:1013 E:1021 ||| NN
compared  ||| S:1021 E:1030 ||| VBN
against  ||| S:1030 E:1038 ||| IN
another  ||| S:1038 E:1046 ||| DT
glucagon-like  ||| S:1046 E:1060 ||| JJ
peptide-1  ||| S:1060 E:1070 ||| CD
agonist ||| S:1070 E:1077 ||| NN
,  ||| S:1077 E:1079 ||| ,
exenatide ||| S:1079 E:1088 ||| CD
] ||| S:1088 E:1089 ||| -RRB-
.  ||| S:1089 E:1091 ||| .
Five  ||| S:1091 E:1096 ||| CD
of  ||| S:1096 E:1099 ||| IN
the  ||| S:1099 E:1103 ||| DT
six  ||| S:1103 E:1107 ||| CD
trials  ||| S:1107 E:1114 ||| NNS
were  ||| S:1114 E:1119 ||| VBD
published  ||| S:1119 E:1129 ||| VBN
in  ||| S:1129 E:1132 ||| IN
full  ||| S:1132 E:1137 ||| JJ
and  ||| S:1137 E:1141 ||| CC
one  ||| S:1141 E:1145 ||| PRP
was  ||| S:1145 E:1149 ||| VBD
then  ||| S:1149 E:1154 ||| RB
unpublished ||| S:1154 E:1165 ||| JJ
.  ||| S:1165 E:1167 ||| .
Two  ||| S:1167 E:1171 ||| CD
doses  ||| S:1171 E:1177 ||| NNS
of  ||| S:1177 E:1180 ||| IN
liraglutide ||| S:1180 E:1191 ||| NN
,  ||| S:1191 E:1193 ||| ,
1.2  ||| S:1193 E:1197 ||| CD
and  ||| S:1197 E:1201 ||| CC
1.8  ||| S:1201 E:1205 ||| CD
mg ||| S:1205 E:1207 ||| NN
,  ||| S:1207 E:1209 ||| ,
were  ||| S:1209 E:1214 ||| VBD
used  ||| S:1214 E:1219 ||| VBN
in  ||| S:1219 E:1222 ||| IN
some  ||| S:1222 E:1227 ||| DT
trials ||| S:1227 E:1233 ||| NNS
,  ||| S:1233 E:1235 ||| ,
but  ||| S:1235 E:1239 ||| CC
in  ||| S:1239 E:1242 ||| IN
the  ||| S:1242 E:1246 ||| DT
two  ||| S:1246 E:1250 ||| CD
comparisons  ||| S:1250 E:1262 ||| NNS
in  ||| S:1262 E:1265 ||| IN
triple  ||| S:1265 E:1272 ||| JJ
therapy ||| S:1272 E:1279 ||| NN
,  ||| S:1279 E:1281 ||| ,
against  ||| S:1281 E:1289 ||| IN
glargine  ||| S:1289 E:1298 ||| NN
and  ||| S:1298 E:1302 ||| CC
exenatide ||| S:1302 E:1311 ||| NN
,  ||| S:1311 E:1313 ||| ,
only  ||| S:1313 E:1318 ||| RB
the  ||| S:1318 E:1322 ||| DT
1.8-mg  ||| S:1322 E:1329 ||| JJ
dose  ||| S:1329 E:1334 ||| NN
was  ||| S:1334 E:1338 ||| VBD
used ||| S:1338 E:1342 ||| VBN
.  ||| S:1342 E:1344 ||| .
Liraglutide  ||| S:1344 E:1356 ||| NNP
in  ||| S:1356 E:1359 ||| IN
both  ||| S:1359 E:1364 ||| DT
doses  ||| S:1364 E:1370 ||| NNS
was  ||| S:1370 E:1374 ||| VBD
found  ||| S:1374 E:1380 ||| VBN
to  ||| S:1380 E:1383 ||| TO
be  ||| S:1383 E:1386 ||| VB
clinically  ||| S:1386 E:1397 ||| RB
effective  ||| S:1397 E:1407 ||| JJ
in  ||| S:1407 E:1410 ||| IN
lowering  ||| S:1410 E:1419 ||| VBG
blood  ||| S:1419 E:1425 ||| NN
glucose  ||| S:1425 E:1433 ||| NN
concentration  ||| S:1433 E:1447 ||| NN
[ ||| S:1447 E:1448 ||| -LRB-
glycated  ||| S:1448 E:1457 ||| FW
haemoglobin  ||| S:1457 E:1469 ||| FW
( ||| S:1469 E:1470 ||| -LRB-
HbA1c ||| S:1470 E:1475 ||| NNP
) ||| S:1475 E:1476 ||| -RRB-
] ||| S:1476 E:1477 ||| -RRB-
,  ||| S:1477 E:1479 ||| ,
reducing  ||| S:1479 E:1488 ||| VBG
weight  ||| S:1488 E:1495 ||| NN
( ||| S:1495 E:1496 ||| -LRB-
unlike  ||| S:1496 E:1503 ||| IN
other  ||| S:1503 E:1509 ||| JJ
glucose-lowering  ||| S:1509 E:1526 ||| JJ
agents ||| S:1526 E:1532 ||| NNS
,  ||| S:1532 E:1534 ||| ,
such  ||| S:1534 E:1539 ||| JJ
as  ||| S:1539 E:1542 ||| IN
sulphonylureas ||| S:1542 E:1556 ||| NN
,  ||| S:1556 E:1558 ||| ,
glitazones  ||| S:1558 E:1569 ||| NN
and  ||| S:1569 E:1573 ||| CC
insulins ||| S:1573 E:1581 ||| NNS
,  ||| S:1581 E:1583 ||| ,
which  ||| S:1583 E:1589 ||| WDT
cause  ||| S:1589 E:1595 ||| VBP
weight  ||| S:1595 E:1602 ||| NN
gain ||| S:1602 E:1606 ||| NN
)  ||| S:1606 E:1608 ||| -RRB-
and  ||| S:1608 E:1612 ||| CC
also  ||| S:1612 E:1617 ||| RB
reducing  ||| S:1617 E:1626 ||| VBG
systolic  ||| S:1626 E:1635 ||| JJ
blood  ||| S:1635 E:1641 ||| NN
pressure  ||| S:1641 E:1650 ||| NN
( ||| S:1650 E:1651 ||| -LRB-
SBP ||| S:1651 E:1654 ||| NNP
) ||| S:1654 E:1655 ||| -RRB-
.  ||| S:1655 E:1657 ||| .
Hypoglycaemia  ||| S:1657 E:1671 ||| NNP
was  ||| S:1671 E:1675 ||| VBD
uncommon ||| S:1675 E:1683 ||| JJ
.  ||| S:1683 E:1685 ||| .
The  ||| S:1685 E:1689 ||| DT
ERG  ||| S:1689 E:1693 ||| NNP
carried  ||| S:1693 E:1701 ||| VBD
out  ||| S:1701 E:1705 ||| RP
meta-analyses  ||| S:1705 E:1719 ||| JJ
comparing  ||| S:1719 E:1729 ||| VBG
the  ||| S:1729 E:1733 ||| DT
1.2-  ||| S:1733 E:1738 ||| NNP
and  ||| S:1738 E:1742 ||| CC
1.8-mg  ||| S:1742 E:1749 ||| CD
doses  ||| S:1749 E:1755 ||| NNS
of  ||| S:1755 E:1758 ||| IN
liraglutide ||| S:1758 E:1769 ||| NN
,  ||| S:1769 E:1771 ||| ,
which  ||| S:1771 E:1777 ||| WDT
suggested  ||| S:1777 E:1787 ||| VBD
that  ||| S:1787 E:1792 ||| IN
there  ||| S:1792 E:1798 ||| EX
was  ||| S:1798 E:1802 ||| VBD
no  ||| S:1802 E:1805 ||| DT
difference  ||| S:1805 E:1816 ||| NN
in  ||| S:1816 E:1819 ||| IN
control  ||| S:1819 E:1827 ||| NN
of  ||| S:1827 E:1830 ||| IN
diabetes ||| S:1830 E:1838 ||| NN
,  ||| S:1838 E:1840 ||| ,
and  ||| S:1840 E:1844 ||| CC
only  ||| S:1844 E:1849 ||| RB
a  ||| S:1849 E:1851 ||| DT
slight  ||| S:1851 E:1858 ||| JJ
difference  ||| S:1858 E:1869 ||| NN
in  ||| S:1869 E:1872 ||| IN
weight  ||| S:1872 E:1879 ||| NN
loss ||| S:1879 E:1883 ||| NN
,  ||| S:1883 E:1885 ||| ,
insufficient  ||| S:1885 E:1898 ||| JJ
to  ||| S:1898 E:1901 ||| TO
justify  ||| S:1901 E:1909 ||| VB
the  ||| S:1909 E:1913 ||| DT
extra  ||| S:1913 E:1919 ||| JJ
cost ||| S:1919 E:1923 ||| NN
.  ||| S:1923 E:1925 ||| .
The  ||| S:1925 E:1929 ||| DT
cost-effectiveness  ||| S:1929 E:1948 ||| JJ
analysis  ||| S:1948 E:1957 ||| NN
was  ||| S:1957 E:1961 ||| VBD
carried  ||| S:1961 E:1969 ||| VBN
out  ||| S:1969 E:1973 ||| RP
using  ||| S:1973 E:1979 ||| VBG
the  ||| S:1979 E:1983 ||| DT
Center  ||| S:1983 E:1990 ||| NNP
for  ||| S:1990 E:1994 ||| IN
Outcomes  ||| S:1994 E:2003 ||| NNP
Research  ||| S:2003 E:2012 ||| NNP
model ||| S:2012 E:2017 ||| NN
.  ||| S:2017 E:2019 ||| .
The  ||| S:2019 E:2023 ||| DT
health  ||| S:2023 E:2030 ||| NN
benefit  ||| S:2030 E:2038 ||| NN
was  ||| S:2038 E:2042 ||| VBD
reported  ||| S:2042 E:2051 ||| VBN
as  ||| S:2051 E:2054 ||| IN
quality-adjusted  ||| S:2054 E:2071 ||| JJ
life-years  ||| S:2071 E:2082 ||| NN
( ||| S:2082 E:2083 ||| -LRB-
QALYs ||| S:2083 E:2088 ||| NNP
) ||| S:2088 E:2089 ||| -RRB-
.  ||| S:2089 E:2091 ||| .
The  ||| S:2091 E:2095 ||| DT
manufacturer  ||| S:2095 E:2108 ||| NN
estimated  ||| S:2108 E:2118 ||| VBD
the  ||| S:2118 E:2122 ||| DT
cost-effectiveness  ||| S:2122 E:2141 ||| JJ
to  ||| S:2141 E:2144 ||| TO
be  ||| S:2144 E:2147 ||| VB
£  ||| S:2147 E:2149 ||| CD
15,130  ||| S:2149 E:2156 ||| CD
per  ||| S:2156 E:2160 ||| IN
QALY  ||| S:2160 E:2165 ||| NNP
for  ||| S:2165 E:2169 ||| IN
liraglutide  ||| S:2169 E:2181 ||| CD
1.8  ||| S:2181 E:2185 ||| CD
mg  ||| S:2185 E:2188 ||| NNS
compared  ||| S:2188 E:2197 ||| VBN
with  ||| S:2197 E:2202 ||| IN
glargine ||| S:2202 E:2210 ||| NN
,  ||| S:2210 E:2212 ||| ,
£  ||| S:2212 E:2214 ||| FW
10,054  ||| S:2214 E:2221 ||| FW
per  ||| S:2221 E:2225 ||| FW
QALY  ||| S:2225 E:2230 ||| NNP
for  ||| S:2230 E:2234 ||| IN
liraglutide  ||| S:2234 E:2246 ||| CD
1.8  ||| S:2246 E:2250 ||| CD
mg  ||| S:2250 E:2253 ||| NNS
compared  ||| S:2253 E:2262 ||| VBN
with  ||| S:2262 E:2267 ||| IN
exenatide ||| S:2267 E:2276 ||| NN
,  ||| S:2276 E:2278 ||| ,
£  ||| S:2278 E:2280 ||| FW
10,465  ||| S:2280 E:2287 ||| FW
per  ||| S:2287 E:2291 ||| FW
QALY  ||| S:2291 E:2296 ||| NNP
for  ||| S:2296 E:2300 ||| IN
liraglutide  ||| S:2300 E:2312 ||| CD
1.8  ||| S:2312 E:2316 ||| CD
mg  ||| S:2316 E:2319 ||| NNS
compared  ||| S:2319 E:2328 ||| VBN
with  ||| S:2328 E:2333 ||| IN
sitagliptin ||| S:2333 E:2344 ||| NN
,  ||| S:2344 E:2346 ||| ,
and  ||| S:2346 E:2350 ||| CC
£  ||| S:2350 E:2352 ||| CD
9851  ||| S:2352 E:2357 ||| CD
per  ||| S:2357 E:2361 ||| IN
QALY  ||| S:2361 E:2366 ||| NNP
for  ||| S:2366 E:2370 ||| IN
liraglutide  ||| S:2370 E:2382 ||| CD
1.2  ||| S:2382 E:2386 ||| CD
mg  ||| S:2386 E:2389 ||| NNS
compared  ||| S:2389 E:2398 ||| VBN
with  ||| S:2398 E:2403 ||| IN
sitagliptin ||| S:2403 E:2414 ||| NN
.  ||| S:2414 E:2416 ||| .
The  ||| S:2416 E:2420 ||| DT
ERG  ||| S:2420 E:2424 ||| NNP
conducted  ||| S:2424 E:2434 ||| VBD
additional  ||| S:2434 E:2445 ||| JJ
sensitivity  ||| S:2445 E:2457 ||| NN
analyses  ||| S:2457 E:2466 ||| NNS
and  ||| S:2466 E:2470 ||| CC
concluded  ||| S:2470 E:2480 ||| VBD
that  ||| S:2480 E:2485 ||| IN
the  ||| S:2485 E:2489 ||| DT
factors  ||| S:2489 E:2497 ||| NNS
that  ||| S:2497 E:2502 ||| WDT
carried  ||| S:2502 E:2510 ||| VBD
most  ||| S:2510 E:2515 ||| JJS
weight  ||| S:2515 E:2522 ||| NN
were ||| S:2522 E:2526 ||| VBD
:  ||| S:2526 E:2528 ||| :
in  ||| S:2528 E:2531 ||| IN
the  ||| S:2531 E:2535 ||| DT
comparison  ||| S:2535 E:2546 ||| NN
with  ||| S:2546 E:2551 ||| IN
glargine ||| S:2551 E:2559 ||| NN
,  ||| S:2559 E:2561 ||| ,
the  ||| S:2561 E:2565 ||| DT
direct  ||| S:2565 E:2572 ||| JJ
utility  ||| S:2572 E:2580 ||| NN
effects  ||| S:2580 E:2588 ||| NNS
of  ||| S:2588 E:2591 ||| IN
body  ||| S:2591 E:2596 ||| NN
mass  ||| S:2596 E:2601 ||| NN
index  ||| S:2601 E:2607 ||| NN
( ||| S:2607 E:2608 ||| -LRB-
BMI ||| S:2608 E:2611 ||| NNP
)  ||| S:2611 E:2613 ||| -RRB-
changes  ||| S:2613 E:2621 ||| NNS
and  ||| S:2621 E:2625 ||| CC
SBP ||| S:2625 E:2628 ||| NNP
,  ||| S:2628 E:2630 ||| ,
with  ||| S:2630 E:2635 ||| IN
some  ||| S:2635 E:2640 ||| DT
additional  ||| S:2640 E:2651 ||| JJ
contribution  ||| S:2651 E:2664 ||| NN
from  ||| S:2664 E:2669 ||| IN
HbA1c ||| S:2669 E:2674 ||| NNP
,  ||| S:2674 E:2676 ||| ,
in  ||| S:2676 E:2679 ||| IN
the  ||| S:2679 E:2683 ||| DT
comparison  ||| S:2683 E:2694 ||| NN
with  ||| S:2694 E:2699 ||| IN
exenatide ||| S:2699 E:2708 ||| NN
,  ||| S:2708 E:2710 ||| ,
HbA1c ||| S:2710 E:2715 ||| NNP
,  ||| S:2715 E:2717 ||| ,
with  ||| S:2717 E:2722 ||| IN
some  ||| S:2722 E:2727 ||| DT
additional  ||| S:2727 E:2738 ||| JJ
effects  ||| S:2738 E:2746 ||| NNS
from  ||| S:2746 E:2751 ||| IN
cholesterol  ||| S:2751 E:2763 ||| NN
and  ||| S:2763 E:2767 ||| CC
triglycerides  ||| S:2767 E:2781 ||| NN
in  ||| S:2781 E:2784 ||| IN
the  ||| S:2784 E:2788 ||| DT
comparison  ||| S:2788 E:2799 ||| NN
with  ||| S:2799 E:2804 ||| IN
sitagliptin ||| S:2804 E:2815 ||| NN
,  ||| S:2815 E:2817 ||| ,
HbA1c  ||| S:2817 E:2823 ||| NNP
and  ||| S:2823 E:2827 ||| CC
direct  ||| S:2827 E:2834 ||| JJ
utility  ||| S:2834 E:2842 ||| NN
effects  ||| S:2842 E:2850 ||| NNS
of  ||| S:2850 E:2853 ||| IN
BMI  ||| S:2853 E:2857 ||| NNP
changes ||| S:2857 E:2864 ||| NNS
.  ||| S:2864 E:2866 ||| .
The  ||| S:2866 E:2870 ||| DT
European  ||| S:2870 E:2879 ||| NNP
Medicines  ||| S:2879 E:2889 ||| NNP
Agency  ||| S:2889 E:2896 ||| NNP
has  ||| S:2896 E:2900 ||| VBZ
approved  ||| S:2900 E:2909 ||| VBN
liraglutide  ||| S:2909 E:2921 ||| VBN
in  ||| S:2921 E:2924 ||| IN
dual  ||| S:2924 E:2929 ||| JJ
therapy  ||| S:2929 E:2937 ||| NN
with  ||| S:2937 E:2942 ||| IN
other  ||| S:2942 E:2948 ||| JJ
oral  ||| S:2948 E:2953 ||| JJ
glucose-lowering  ||| S:2953 E:2970 ||| JJ
agents ||| S:2970 E:2976 ||| NNS
.  ||| S:2976 E:2978 ||| .
NICE  ||| S:2978 E:2983 ||| JJ
guidance  ||| S:2983 E:2992 ||| NN
recommends  ||| S:2992 E:3003 ||| VBZ
the  ||| S:3003 E:3007 ||| DT
use  ||| S:3007 E:3011 ||| NN
of  ||| S:3011 E:3014 ||| IN
liraglutide  ||| S:3014 E:3026 ||| CD
1.2  ||| S:3026 E:3030 ||| CD
mg  ||| S:3030 E:3033 ||| NN
in  ||| S:3033 E:3036 ||| IN
triple  ||| S:3036 E:3043 ||| JJ
therapy  ||| S:3043 E:3051 ||| NN
when  ||| S:3051 E:3056 ||| WRB
glycaemic  ||| S:3056 E:3066 ||| JJ
control  ||| S:3066 E:3074 ||| NN
remains  ||| S:3074 E:3082 ||| VBZ
or  ||| S:3082 E:3085 ||| CC
becomes  ||| S:3085 E:3093 ||| VBZ
inadequate  ||| S:3093 E:3104 ||| JJ
with  ||| S:3104 E:3109 ||| IN
a  ||| S:3109 E:3111 ||| DT
combination  ||| S:3111 E:3123 ||| NN
of  ||| S:3123 E:3126 ||| IN
two  ||| S:3126 E:3130 ||| CD
oral  ||| S:3130 E:3135 ||| JJ
glucose-lowering  ||| S:3135 E:3152 ||| JJ
drugs ||| S:3152 E:3157 ||| NNS
.  ||| S:3157 E:3159 ||| .
The  ||| S:3159 E:3163 ||| DT
use  ||| S:3163 E:3167 ||| NN
of  ||| S:3167 E:3170 ||| IN
liraglutide  ||| S:3170 E:3182 ||| CD
1.2  ||| S:3182 E:3186 ||| CD
mg  ||| S:3186 E:3189 ||| NN
in  ||| S:3189 E:3192 ||| IN
a  ||| S:3192 E:3194 ||| DT
dual  ||| S:3194 E:3199 ||| JJ
therapy  ||| S:3199 E:3207 ||| NN
is  ||| S:3207 E:3210 ||| VBZ
indicated  ||| S:3210 E:3220 ||| VBN
only  ||| S:3220 E:3225 ||| RB
in  ||| S:3225 E:3228 ||| IN
patients  ||| S:3228 E:3237 ||| NNS
who  ||| S:3237 E:3241 ||| WP
are  ||| S:3241 E:3245 ||| VBP
intolerant  ||| S:3245 E:3256 ||| VBN
of ||| S:3256 E:3258 ||| IN
,  ||| S:3258 E:3260 ||| ,
or  ||| S:3260 E:3263 ||| CC
have  ||| S:3263 E:3268 ||| VBP
contraindications  ||| S:3268 E:3286 ||| VBN
to ||| S:3286 E:3288 ||| TO
,  ||| S:3288 E:3290 ||| ,
three  ||| S:3290 E:3296 ||| CD
oral  ||| S:3296 E:3301 ||| JJ
glucose-lowering  ||| S:3301 E:3318 ||| JJ
drugs ||| S:3318 E:3323 ||| NNS
.  ||| S:3323 E:3325 ||| .
The  ||| S:3325 E:3329 ||| DT
use  ||| S:3329 E:3333 ||| NN
of  ||| S:3333 E:3336 ||| IN
liraglutide  ||| S:3336 E:3348 ||| CD
1.8  ||| S:3348 E:3352 ||| CD
mg  ||| S:3352 E:3355 ||| NNS
was  ||| S:3355 E:3359 ||| VBD
not  ||| S:3359 E:3363 ||| RB
approved  ||| S:3363 E:3372 ||| VBN
by  ||| S:3372 E:3375 ||| IN
NICE ||| S:3375 E:3379 ||| NNP
.  ||| S:3379 E:3381 ||| .
The  ||| S:3381 E:3385 ||| DT
ERG  ||| S:3385 E:3389 ||| NNP
recommends  ||| S:3389 E:3400 ||| VBZ
research  ||| S:3400 E:3409 ||| NN
into  ||| S:3409 E:3414 ||| IN
the  ||| S:3414 E:3418 ||| DT
( ||| S:3418 E:3419 ||| -LRB-
currently  ||| S:3419 E:3429 ||| RB
unlicensed ||| S:3429 E:3439 ||| CD
)  ||| S:3439 E:3441 ||| -RRB-
use  ||| S:3441 E:3445 ||| NN
of  ||| S:3445 E:3448 ||| IN
liraglutide  ||| S:3448 E:3460 ||| NN
in  ||| S:3460 E:3463 ||| IN
combination  ||| S:3463 E:3475 ||| NN
with  ||| S:3475 E:3480 ||| IN
long-acting  ||| S:3480 E:3492 ||| JJ
insulin ||| S:3492 E:3499 ||| NN
.  ||| S:3499 E:3501 ||| .
